This inventor holds 5 USPTO granted patents and 4 published patent applications and 1 EPO patent. Top assignee: Novartis Ag. Active years: 2016-2020.
Company Filing History:
Years Active: 2016-2020
Title: Kurt Alex Heldwein: Innovator in Cardiovascular Treatment
Introduction
Kurt Alex Heldwein is a notable inventor based in Belmont, MA (US). He has made significant contributions to the field of medicine, particularly in the development of treatments for cardiovascular disorders. With a total of 5 patents to his name, Heldwein's work has the potential to impact many lives.
Latest Patents
Among his latest patents are two key inventions related to monoclonal antibodies. The first patent, titled "Nucleic acids encoding lectin-like oxidized LDL receptor 1 antibodies," focuses on antibodies that bind to human lectin-like oxidized LDL (low density lipoprotein) receptor 1, also known as LOX-1. This invention includes pharmaceutical compositions and methods of treatment that utilize these antibodies. The second patent, "Methods of treating cardiovascular disorders with lectin-like oxidized LDL receptor 1 antibodies," further explores the therapeutic applications of LOX-1 antibodies in treating cardiovascular conditions.
Career Highlights
Kurt Alex Heldwein is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to collaborate with other experts in the field and contribute to innovative medical solutions.
Collaborations
Some of his notable coworkers include Jennifer Brogdon and William Dole. Their collaborative efforts have likely enhanced the research and development of new treatments in the cardiovascular domain.
Conclusion
Kurt Alex Heldwein's contributions to the field of cardiovascular treatment through his innovative patents demonstrate his commitment to advancing medical science. His work continues to pave the way for new therapeutic options that could benefit countless patients.